Ebrahim Salehifar

Dr. Ebrahim Salehifar

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2008 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
MSMohammad Shokrzadeh
Mohammad Shokrzadeh
AGAli Ghaemian
Ali Ghaemian
ESEbrahim Salehifar
Ebrahim Salehifar
SASoudabeh Aliakbari
Soudabeh Aliakbari
SSSeyyed Soheil Saeedi Saravi
Seyyed Soheil Saeedi Saravi
PEPooneh Ebrahimi
Pooneh Ebrahimi

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MRMohammad Sadegh Rezai
Mohammad Sadegh Rezai
ESEbrahim Salehifar
Ebrahim Salehifar
ARAlireza Rafiei
Alireza Rafiei
TLTaimour Langaee
Taimour Langaee
MRMohammadreza Rafati
Mohammadreza Rafati
GEGohar Eslami
Gohar Eslami
Escherichia coliremains as one of the most important bacteria causing infections in pediatrics and producing extended-spectrum beta-lactamases (ESBLs) making them resistant to beta-lactam antibiotics. In this study we aimed to genotype ESBL-producingE. coliisolates from pediatric patients for ESBL genes and determine their association with antimicrobial resistance. One hundred of theE. coliisolates were initially considered ESBL producing based on their MIC results. These isolates were then tested by polymerase chain reaction (PCR) for the presence or absence ofCTX,TEM,SHV,GES, andVEBbeta-lactamase genes. About 30.5% of isolatedE. coliwas ESBL-producing strain. TheTEMgene was the most prevalent (49%) followed bySHV(44%),CTX(28%),VEB(8%), andGES(0%) genes. The ESBL-producingE. coliisolates were susceptible to carbapenems (66%) and amikacin (58%) and showed high resistance to cefixime (99%), colistin (82%), and ciprofloxacin (76%). In conclusion, carbapenems were the most effective antibiotics against ESBl-producingE. coliin urinary tract infection in North of Iran. The most prevalent gene is the TEM-type, but the other resistant genes and their antimicrobial resistance are on the rise.

10 January 2020 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
ESEbrahim Salehifar
Ebrahim Salehifar
GJGhasem Janbabaei
Ghasem Janbabaei
NHNarjes Hendouei
Narjes Hendouei
AAAbbas Alipour
Abbas Alipour
NTNasim Tabrizi
Nasim Tabrizi
RARazieh Avan
Razieh Avan

16 June 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RNReza Negarandeh
Reza Negarandeh
ESEbrahim Salehifar
Ebrahim Salehifar
FSFatemeh Saghafi
Fatemeh Saghafi
HJHossein Jalali
Hossein Jalali
GJGhasem Janbabaei
Ghasem Janbabaei
ANAnahita Nosrati
Anahita Nosrati
Background: 5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine derivatives that mainly metabolized with dihydropyrimidine dehydrogenase enzyme (DPD). The genetic polymorphism in the genes encoding this enzyme may result in a decrease or loss of enzyme activity which may lead to the accumulation of medicines, their metabolites and potential toxicity. Method: This cross-sectional study was conducted on 88 participants with colorectal cancer (CRC). After DNA extraction, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to determine the DPD gene (DPYD) polymorphisms including IVS 14 + 1 G > A, 2846 A > T and 2194 G > A. Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5.0). Result: Data were collected from 227 chemotherapy cycles of 88 patients with CRC. In a comparison of FOLFOX and FOLFIRI regimens, there was no significant difference in the occurrence of chemotherapy-induced diarrhea, nausea, vomiting and oral mucositis. However, the peripheral neuropathy was more frequent in patients who were treated with FOLFOX (P < 0.001) and hair loss was more common in patients who received FOLFIRI regimen (P = 0.048). Incidence of the DPD IVS14 + 1 G > A polymorphism was observed in four patients (5.5%). There was no association between IVS14 + 1 G > A polymorphism and the occurrence of adverse reactions. Conclusion: FOLFOX and FOLFIRI were the most common regimens in CRC patients and their toxicity profile was different in some adverse reactions. Prevalence of IVS14 + 1G > A variant was relatively higher than other similar studies. Trial registration: Approval code; IR.MAZUMS.REC.95.2480.

1 January 2018 in Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
ESEbrahim Salehifar
Ebrahim Salehifar
RARazieh Avan
Razieh Avan
GJGhasem Janbabaei
Ghasem Janbabaei
NHNarjes Hendouei
Narjes Hendouei
AAAbbas Alipour
Abbas Alipour
NTNasim Tabrizi
Nasim Tabrizi
Background: The primary side effect of adjuvant chemotherapy with taxanes is the taxane-induced peripheral neuropathy (TIPN), which may have substantial negative impacts on patients' quality of life (QOL). We investigated the effect of pregabalin and duloxetine on QOL of breast cancer patients who experienced TIPN. Materials and Methods: This was a randomized, double-blind clinical trial conducted at a chemotherapy center of Mazandaran University of Medical Sciences, Sari, Iran. Breast cancer patients 18 or more years old were included if they received paclitaxel or docetaxel and experienced neuropathy grade one or higher; and neuropathic pain score of four or more. Patients were treated with pregabalin or duloxetine until 6 weeks. Assessment of sensory neuropathy and QOL was performed at baseline, and 6 weeks after the initiation of the treatment. Results: At baseline, the mean score of global health status/QOL scale for pregabalin and duloxetine groups were 61 (standard deviation [SD]; 5.11) and 60.28 (SD; 5.44), respectively (P = 0.54). After 6 weeks, both interventions were associated with improvement of global QOL compared to baseline. The global health status/QOL score was not different between two groups after 6 weeks. While the emotional functioning was improved more favorably with duloxetine (P < 0.001); pregabalin was associated with more improvement in insomnia and pain scores (P = 0.05 and P < 0.001, respectively). Conclusion: Pregabalin as well as duloxetine improve the global QOL of breast cancer patients with TIPN. Different effects of treatments on subscale of QLQ-C30 could help clinicians to select the appropriate agent individually.

1 April 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
ESEbrahim Salehifar
Ebrahim Salehifar
SHSeyed Jalal Hosseinimehr
Seyed Jalal Hosseinimehr